197 related articles for article (PubMed ID: 9588734)
1. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
Mok CC; Lau CS; Wong RW
Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
[TBL] [Abstract][Full Text] [Related]
2. Ovarian failure and flares of systemic lupus erythematosus.
Mok CC; Wong RW; Lau CS
Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
[TBL] [Abstract][Full Text] [Related]
3. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].
Yang XY; Zhu X; Liang LQ; Zhan ZP; Ye YJ
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):960-2. PubMed ID: 16061002
[TBL] [Abstract][Full Text] [Related]
4. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
5. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
[TBL] [Abstract][Full Text] [Related]
6. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A
Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
8. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.
Ioannidis JP; Katsifis GE; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2002 Oct; 29(10):2129-35. PubMed ID: 12375322
[TBL] [Abstract][Full Text] [Related]
9. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
Manger K; Wildt L; Kalden JR; Manger B
Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
[TBL] [Abstract][Full Text] [Related]
10. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
Vlachoyiannopoulos PG; Toya SP; Katsifis G; Zintzaras E; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide boluses induce micronuclei expression in buccal mucosa cells of patients with systemic lupus erythematosus independent of cytochrome P450 2D6 status.
Aceves Avila FJ; Esquivel Nava GA; Gallegos Arreola MP; Gómez Meda B; Zúñiga González G; Ramos-Remus C
J Rheumatol; 2004 Jul; 31(7):1335-9. PubMed ID: 15229952
[TBL] [Abstract][Full Text] [Related]
13. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
Mok CC; Chan PT; To CH
Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
Singh G; Saxena N; Aggarwal A; Misra R
J Rheumatol; 2007 Apr; 34(4):731-3. PubMed ID: 17407229
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
[TBL] [Abstract][Full Text] [Related]
16. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
[TBL] [Abstract][Full Text] [Related]
17. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
Laskari K; Zintzaras E; Tzioufas AG
Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
[TBL] [Abstract][Full Text] [Related]
18. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.
Faurschou M; Sorensen IJ; Mellemkjaer L; Loft AG; Thomsen BS; Tvede N; Baslund B
J Rheumatol; 2008 Jan; 35(1):100-5. PubMed ID: 17937462
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.
Zhang CY; Lu LJ; Li FH; Li HL; Gu YY; Chen SL; Bao CD
J Clin Rheumatol; 2009 Apr; 15(3):111-6. PubMed ID: 19300290
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]